Notwithstanding positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from PBMs. These organizations are typically erecting barriers to access, such as significant expense requirements and approval processes that hinder user opportunity. Analy